 Antiviral Agents
"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 7 | 2 | 9 | | 1998 | 4 | 2 | 6 | | 1999 | 1 | 0 | 1 | | 2000 | 4 | 0 | 4 | | 2001 | 3 | 2 | 5 | | 2002 | 6 | 3 | 9 | | 2003 | 7 | 0 | 7 | | 2004 | 8 | 6 | 14 | | 2005 | 5 | 4 | 9 | | 2006 | 6 | 3 | 9 | | 2007 | 11 | 6 | 17 | | 2008 | 7 | 5 | 12 | | 2009 | 8 | 6 | 14 | | 2010 | 7 | 6 | 13 | | 2011 | 9 | 10 | 19 | | 2012 | 14 | 1 | 15 | | 2013 | 16 | 1 | 17 | | 2014 | 10 | 5 | 15 | | 2015 | 25 | 11 | 36 | | 2016 | 23 | 5 | 28 | | 2017 | 15 | 7 | 22 | | 2018 | 18 | 7 | 25 | | 2019 | 19 | 10 | 29 | | 2020 | 21 | 15 | 36 | | 2021 | 21 | 13 | 34 | | 2022 | 9 | 30 | 39 | | 2023 | 2 | 18 | 20 | | 2024 | 14 | 8 | 22 | | 2025 | 20 | 3 | 23 | | 2026 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Hecht CJS, Parker RR. RK-33 inhibits the OC43 coronavirus and induces stress granules via DDX3X-independent mechanisms. RNA. 2026 Apr 16; 32(5):724-735.
-
Li K, Rudy MJ, Klose T, Tan H, Wu X, Demssie HA, Anderson JS, Jadhav P, Zhang QY, Clarke P, Kuhn RJ, Tyler KL, Wang J. Rational design and in vivo validation of capsid inhibitors for enterovirus D68. Nat Commun. 2026 Feb 10; 17(1).
-
Kim AY, Kang M, Umbleja T, Nunes EP, Marks KM, Luetkemeyer AF, Koebele C, Wimbish C, Fierer DS, Kliemann DA, Solomon SS, Kort J, Kiser JJ, Lauer GM, Chung RT, Sowah LA, Alston-Smith BL, Wyles DL, Naggie S. Short Course Therapy With Glecaprevir/Pibrentasvir for Early Hepatitis C Virus Infection: PURGE-C. Clin Infect Dis. 2026 Feb 04; 81(6):1083-1090.
-
Shah MM, Abedi GR, Lu S, Garcia-Knight M, Pineda-Ramirez J, Goldberg SA, Grijalva CG, Keipp Talbot H, Schmitz J, Lutrick K, Ellingson KD, Stockwell MS, Sano E, Nguyen HQ, Rao S, Asturias EJ, Suthar MS, Mellis AM, Deeks SG, Martin JN, Peluso MJ, Andino R, Rolfes MA, Kirking HL, Smith-Jeffcoat SE, Midgley CM, Hagen MB, Kelly JD. SARS-CoV-2 infectious shedding and rebound among adults with and without oral antiviral use: two case-ascertained prospective household studies. Lancet Microbe. 2026 Jan; 7(1):101227.
-
Sears JD, Popov KI, Sylvester PA, Dickmander R, Diaz J, Chang CK, Huff J, Sanders W, Saba NA, Sorensen M, Drobish AM, May NA, Namitz K, Fecko J, Yennawar NH, Morrison TE, Tropsha A, Heise MT, Moorman NJ. Novel computational pipeline to identify target sites for broad spectrum antiviral drugs. Antiviral Res. 2026 01; 245:106322.
-
Concannon K, Page R, Swayngim R, Ambardekar AV, Chiu CY, Schoeppler K, Sartain E. Low-Dose Valganciclovir for Primary Cytomegalovirus Prophylaxis After Heart Transplant: A 10-Year Experience. Clin Transplant. 2025 Dec; 39(12):e70408.
-
Adams K, Garg S, Tartof SY, Irving SA, DeSilva MB, Klein NP, Natarajan K, Dascomb K, Grannis SJ, Ong TC, Salas SB, Sy LS, Lewin B, Qian L, Naleway AL, Koppolu PD, McEvoy CE, Akinsete O, Essien I, Fireman B, Zerbo O, Jacobson KB, Timbol J, Neelam V, Reeves EL, Dickerson M, Ray C, Link-Gelles R, Mak J, Ball SW, O'Reilly M, Olsen SJ, Tenforde MW. Patterns in Prescribing and Dispensing Influenza Antivirals Among Adults With Influenza Presenting to Urgent Care and Emergency Department Settings: VISION Network, 2023-2024. Clin Infect Dis. 2025 Nov 06; 81(4):e172-e183.
-
Agarwal T, Beaty LE, Carlson NE, Bennett TD, Fish LE, Mayer DA, Molina KC, Peers JL, Webb BJ, Xiao M, Ginde AA, Aggarwal NR. Association of remdesivir treatment with long-term mortality after COVID-19 hospitalization. BMC Infect Dis. 2025 Oct 28; 25(1):1418.
-
Pasco R, Hayden FG, Meyers LA. Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. J Infect Dis. 2025 Oct 17; 232(Supplement_3):S299-S308.
-
Pentyala A, Kandel SE, Lampe JN. Mechanistic insights into human carboxylesterase 2 (CES2) inhibition by the CES1 prodrug substrate remdesivir. Drug Metab Dispos. 2025 Oct; 53(10):100158.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|